Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $130 from $123 and keeps an Overweight rating on the ...

Gilead's fourth quarter was the first full three-month period since it launched Livdelzi, the marquee drug in the company's $4.3 billion March acquisition of CymaBay Therapeutics of Newark.

Livdelzi Sales Can Eventually Grow Based On Several Factors The first considerable opportunity I want to go over with Gilead Sciences would be its enormous feat of being able to obtain Accelerated ...

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...

Gilead's newly launched primary biliary cholangitis treatment Livdelzi is “definitely exceeding our internal expectations,” Mercier said. The August approval marked Gilead’s first in the ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Our liver portfolio, which amounts to a $3 billion business today, is a steady contributor for Gilead, and we look forward to seeing it evolve with the new impetus of Livdelzi. We also continue to ...

Gilead's diversified growth includes significant gains in oncology and liver disease, with Trodelvy and Livdelzi showing strong sales and robust potential for growth. 2025 milestones include ...

Gilead demonstrated solid momentum in the PrEP market, with approximately 16% year-over-year growth, and successes such as the outperformance of Trodelvy and the introduction of Livdelzi.

Report pregnancies to Gilead Sciences, Inc., at 1-800-445-3235. Lactation: There are no data on the presence of LIVDELZI in human milk, the effects on the breastfed infant, or the effects on milk ...